Literature DB >> 20466223

Efficacy of tramadol vs meperidine in vasoocclusive sickle cell crisis.

Belkan Uzun1, Zeynep Kekec, Emel Gurkan.   

Abstract

Despite progress in management, patients with sickle cell disease who are experiencing acute painful episode are often incompletely treated. We compared meperidine and tramadol with respect to their effects on the hemodynamics and pain relief in patients with sickle cell disease who were admitted to the emergency department with painful crisis. A total of 68 patients with sickle cell disease were randomly assigned to receive either tramadol 1.5 mg/kg (n = 34) or meperidine 1 mg/kg (n = 34). Hemodynamic parameters were recorded at regular intervals after analgesic infusions. Pain intensity and relief were documented by visual analog and pain relief scale, respectively. Sedation level was defined according to Ramsay sedation scale. Both meperidine and tramadol administration resulted in a significant reduction in systolic and diastolic blood pressure after 2 hours (P < .05). Efficacy in pain relief between the analgesics was more rapid and better in the meperidine group, although the degree of relief were significantly improved compared to baseline levels in both groups (P < .05). Sedation was more commonly seen in the meperidine arm. None of the patients had experienced neurotoxicity. In summary, both agents had proven safe and effective for emergent use in patients with sickle cell disease. Avoiding meperidine injections as recommended with previous guidelines needs to be carefully reconsidered especially when low doses are mentioned. (c) 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466223     DOI: 10.1016/j.ajem.2009.01.016

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  8 in total

1.  A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD).

Authors:  Paula Tanabe; Susan Silva; Hayden B Bosworth; Regina Crawford; Judith A Paice; Lynne D Richardson; Christopher N Miller; Jeffrey Glassberg
Journal:  Am J Hematol       Date:  2017-11-10       Impact factor: 10.047

2.  Ketamine administration for acute painful sickle cell crisis: A randomized controlled trial.

Authors:  Mohammed S Alshahrani; Amal H AlSulaibikh; Mohamed R ElTahan; Sukayna Z AlFaraj; Laila P Asonto; Abdullah A AlMulhim; Murad F AlAbbad; Nisreen Almaghraby; Mohammed A AlJumaan; Thamir O AlJunaid; Moath N Darweesh; Faisal M AlHawaj; Alaa M Mahmoud; Bader K Alossaimi; Shaikhah K Alotaibi; Talal M AlMutairi; Duaa A AlSulaiman PharmD; Dunya Alfaraj; Reem Alhawwas; Lawrence Mbuagbaw; Kim Lewis; Madeleine Verhovsek; Mark Crowther; Gordon Guyatt; Waleed Alhazzani
Journal:  Acad Emerg Med       Date:  2021-09-21       Impact factor: 5.221

3.  Mechanisms of pain in sickle cell disease.

Authors:  Kensuke Takaoka; Asha Caroline Cyril; Sandhya Jinesh; Rajan Radhakrishnan
Journal:  Br J Pain       Date:  2020-05-22

Review 4.  Acute Chest Syndrome in Children with Sickle Cell Disease.

Authors:  Shilpa Jain; Nitya Bakshi; Lakshmanan Krishnamurti
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2017-12-01       Impact factor: 1.349

5.  The Use of Cannabis by Patients with Sickle Cell Disease Increased the Frequency of Hospitalization due to Vaso-Occlusive Crises.

Authors:  Samir K Ballas
Journal:  Cannabis Cannabinoid Res       Date:  2017-07-01

6.  Study protocol for a randomized, blinded, controlled trial of ketamine for acute painful crisis of sickle cell disease.

Authors:  Mohammed S Alshahrani; Laila Perlas Asonto; Mohamed M El Tahan; Amal H Al Sulaibikh; Sukayna Z Al Faraj; Abdullah A Al Mulhim; Murad F Al Abbad; Samar A Al Nahhash; Moath N Aldarweesh; Alaa M Mahmoud; Nisreen Almaghraby; Mohammed A Al Jumaan; Thamir O Al Junaid; Faisal M Al Hawaj; Samar AlKenany; Omaima F ElSayed; Haitham M Abdelwahab; Mohamed M Moussa; Bader K Alossaimi; Shaikah K Alotaibi; Talal M AlMutairi; Duaa A AlSulaiman; Saad D Al Shahrani; Donia Alfaraj; Waleed Alhazzani
Journal:  Trials       Date:  2019-05-27       Impact factor: 2.279

7.  Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults.

Authors:  Tess E Cooper; Ian R Hambleton; Samir K Ballas; Brydee A Johnston; Philip J Wiffen
Journal:  Cochrane Database Syst Rev       Date:  2019-11-14

8.  Drugs for preventing red blood cell dehydration in people with sickle cell disease.

Authors:  Srikanth Nagalla; Samir K Ballas
Journal:  Cochrane Database Syst Rev       Date:  2018-10-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.